Incyte (INCY) shares have shown solid momentum over the past month, gaining 12% and delivering a 21% return over the past 3 months. The company continues to draw investor attention for its performance ...
Incyte (NASDAQ:INCY) said it would end a phase 3 program examining its myelofibrosis candidate parsaclisib with Jakafi (ruxolitinib) after an interim analysis showed the study was unlikely to meet its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback